Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patent News Round Up: Supreme Court Asked To Review Plavix Patent; New Director May Scrap PTO Rules; Patenting Of Natural Process Debated

Executive Summary

Apotex really wants to get a generic version of Plavix (clopidogrel) on the market before the patent on the drug expires in 2011. Defeated in its efforts to get the patent ruled invalid, the company has asked the Supreme Court to take up the case

You may also be interested in...



PTO Rescinds Regs Reviled By Pharma, But Rule-Making Battle Continues

While biotech and pharma companies continue to face myriad patent battles they have one less worry now that the U.S. Patent and Trademark Office has dropped its controversial rules to limit the number of patent claims and continuation filings an applicant may submit

PTO Rescinds Regs Reviled By Pharma, But Rule-Making Battle Continues

While biotech and pharma companies continue to face myriad patent battles they have one less worry now that the U.S. Patent and Trademark Office has dropped its controversial rules to limit the number of patent claims and continuation filings an applicant may submit

Patent Rule On Continuations Is Invalid; Three Others May Still Bite Pharma

The drug industry won a partial victory in its battle with the U.S. Patent and Trademark Office over rules to limit certain patent filings

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS051335

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel